
Protagonist Therapeutics (PTGX) Stock Forecast & Price Target
Protagonist Therapeutics (PTGX) Analyst Ratings
Bulls say
Protagonist Therapeutics Inc. showcases a promising financial outlook, underpinned by an increased EV/Sales multiple of 9.5x, reflecting the company's growth potential bolstered by anticipated milestone payments and royalties contributing to high margins. Market penetration projections for its drug icotrokinra have been raised, estimating a peak unadjusted revenue of $3.2 billion in psoriasis and $3 billion in ulcerative colitis, indicating a significant increase in market expectations. Additionally, the potential clinical success of pipeline candidates, including preclinical assets, could further enhance share value and market position as they are explored across various indications.
Bears say
Protagonist Therapeutics Inc faces significant challenges that contribute to a negative outlook for its stock, primarily due to potential delays or rejections of pipeline asset approvals, which could substantially reduce future cash flows and negatively affect share price. Additionally, ongoing net losses are anticipated until product approval and commercialization, necessitating further capital raises that may dilute shareholder value. The company also encounters regulatory risks and difficulties in patient recruitment for trials, which may jeopardize the timely progress and success of its drug candidates.
This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Protagonist Therapeutics (PTGX) Analyst Forecast & Price Prediction
Start investing in Protagonist Therapeutics (PTGX)
Order type
Buy in
Order amount
Est. shares
0 shares